Daniel J. Brennan Files Initial Form 3 as Director of Vertex Pharmaceuticals with No Initial Holdings
VERTEX PHARMACEUTICALS INC / MA
Subscribe to track VRTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📋 Form 3 Initial Statement of Beneficial Ownership Issuer: VERTEX PHARMACEUTICALS INC / MA ($VRTX) Insider: Brennan Daniel J. (Director) Event Date: 2026-10-20 Filing Date: 2026-10-22 Holdings Reported: No securities beneficially owned Significance: Low
Comprehensive Analysis
Executive Summary
On October 22, 2026, Daniel J. Brennan filed an initial Form 3 with the U.S. Securities and Exchange Commission, disclosing his status as a newly appointed Director of Vertex Pharmaceuticals Inc. ($VRTX), effective October 20, 2026. The filing indicates that Mr. Brennan currently holds no securities of the company.
Filing Details
- Reporting Person: Daniel J. Brennan
- Role: Director
- Issuer: Vertex Pharmaceuticals Inc. ($VRTX)
- Event Date: October 20, 2026
- Initial Holdings: 0 shares (Form 3 marked
<noSecuritiesOwned>1</noSecuritiesOwned>) - Derivative Holdings: None reported
- Exhibit: Exhibit 24 (Power of Attorney) included, executed on October 15, 2026
Market and Trading Assessment
This filing represents an administrative initial statement of beneficial ownership following Mr. Brennan's appointment to the Board of Directors. As there were no open-market purchases, sales, or pre-existing shareholdings disclosed, this event carries Low trading significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.